Research Updates
CJC-1295 and GH Pulses: Why Formulation Matters More Than a Timing Claim
A human study preserved GH pulsatility during long-acting CJC-1295 exposure. It did not compare bedtime with twice-daily CJC-1295/ipamorelin blends.
Published by PeptideSchool Editorial Desk
A frequently cited CJC-1295 study examined a long-acting, albumin-binding compound. It cannot choose between once-nightly and twice-daily schedules for a different formulation combined with ipamorelin.
The study sampled a whole night
Researchers measured growth hormone every 20 minutes over 12 hours in healthy men, before and one week after a single CJC-1295 injection. Pulse frequency and magnitude were not significantly changed. The more prominent change was a rise in the lower, between-pulse GH level, alongside higher mean GH and IGF-I. CJC-1295 pulsatility study.
The compound's long exposure was central to that experiment. A product described as “no DAC” should not be assumed to share the albumin-binding formulation tested in this paper.
What ipamorelin contributes to the evidence
A separate human study used intravenous ipamorelin and modeled the relationship between its concentration and GH release. It recorded a discrete GH response after administration. That study examined ipamorelin itself, not a CJC-1295 blend or a bedtime-versus-twice-daily comparison. Human ipamorelin study.
Combining the conclusions of two separate papers does not create a third experiment. Different routes and formulations change which comparisons are reasonable.
A timing study would need a direct comparison
To support a schedule claim, researchers would need to hold the formulation and total exposure appropriately controlled while comparing the schedules. They would also need a defined outcome: GH pulse pattern, IGF-I response, adverse events, or a clinical endpoint. A larger hormone measurement is not automatically a better result.
For research notes, record the exact compound, whether albumin binding was involved, delivery route, sampling duration, and comparator. “CJC-1295 study” alone leaves out the details that determine whether the paper applies.
The defensible conclusion is about evidence matching: the 2006 study supports a specific finding about GH pulsatility under long-acting CJC-1295 stimulation. It supplies no validated timing schedule for a no-DAC/ipamorelin mixture.
References
Sources
Educational content only. Not medical advice.